BioVendor Presents Fully Automated CLIA Solution for Complex Diagnostics

BioVendor Group (Brno, Czech Republic) has introduced a fully automated CLIA solution, unique in its diagnostic scope, reliability and level of technological sophistication, for complex diagnostics.

The BioVendor Group CLIA brand has arrived through the cooperation of companies within this biotechnology group. Their development and manufacture of diagnostic kits for the new KleeYa analyzer from Diatron has created an automated, entirely European solution using a modern chemiluminescence method - CLIA. In recent years CLIA has won recognition in the diagnostic world, replacing traditional methods such as ELISA and RIA thanks to the reduction in measurement time and automation. The collaboration between BioVendor R&D development division for innovative biomarkers and technologies, engaged in research since 1995, and TestLine, a manufacturer of IVD products for infectious diseases and immunology since the 1990’s, has been strengthened by the knowledge and experience contributed by DiaSource in the diagnostic fields of endocrinology and autoimmune disease.

This fully automated solution combines experience in developing and producing diagnostic kits from individual BioVendor Group associates. The quality of the instrument is guaranteed by the established manufacturer Diatron, which belongs to the Stratec portfolio. The cooperation of companies from several fields enables the BioVendor Group to compile specific panels and design the composition of assays for much more complex testing and offer patients meaningful multidisciplinary diagnostics. The BioVendor Group CLIA solution is suitable for both smaller and large laboratories, in which it will complement the existing portfolio. To smaller workplaces it brings automation and the ability to test a number of parameters quickly in response to immediate needs. The BioVendor Group CLIA solution has the advantage of augmented reality service support, allowing users to solve user problems immediately without the need to wait for the arrival of a technician. The customer line offers clients support 24 hours a day.

BioVendor Group develops unique parameters that differentiate this solution from others on the market. The goal is to provide laboratories with instrument and diagnostic kits as a fine-tuned system that will facilitate the diagnosis of individual diseases effectively. Due to the complexity, they can, for example, find out from one sample whether the test subject is infected with one type of disease and point out a possible initial stage of another illness. One such unique parameter is MxA which has more than one application. In vulnerable individuals such as newborn infants, MxA can be used to identify potentially dangerous viral infections of the upper respiratory tract. In patients with multiple sclerosis or Sjögren's syndrome, it may indicate a reduced effectiveness of treatment and thus prevent an irreversible deterioration in their health.

BioVendor Group is gradually expanding individual clinical testing with new parameters. The present solution focuses on infectious diseases, including COVID-19, sepsis and inflammation, immunological and autoimmune diseases, as well as fertility and endocrinology. Connecting test parameters from specific clinical areas will provide a more comprehensive picture of the health of each individual. The BioVendor Group CLIA development pipeline will result in diagnostic kits for the KleeYa platform in clinical areas including cardiovascular disease, diabetes and metabolic disorders, bone and cartilage metabolism or kidney disease and oncology. The BioVendor Group is developing and certifying individual diagnostic kits CE IVD, and the number of unique and routinely established parameters will increase progressively. At this moment, laboratories can monitor the antibody response to COVID-19 infection and the effectiveness of vaccination against the disease using the CLIA solution from the BioVendor Group. In addition, other parameters will be added for areas of sepsis and inflammation or infectious serology.

“We are putting the best of the collective tradition of all BioVendor Group companies into the new, automated solution. Both from a tangible point of view, where diagnostic tests can be mentioned, but also from the intangible point of view, where I would like to highlight decades of experience in cooperation and care for our customers,” said Michal Kostka D.V.M, CEO of BioVendor Group. “Laboratory diagnostics is one of the fields where automation and consolidation is on the rise, so we also want to continue to participate in the development of modern diagnostic methods and thus benefit from the many years of experience of companies belonging to the BioVendor Group.”

Related Links:
BioVendor Group